Skip to main content
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.
What are you looking for?

Four Insights From Healthcare Providers on the Frontlines of Cancer Treatment

Syneos Health surveyed 78 healthcare providers to understand how oncology and hematology clinical trials are impacting their patients.

From new developments in treatment modalities to improved standards of care to the latest in precision-medicine for breast, lung and gastrointestinal cancers, clinical trials are advancing treatments for oncology and hematology at an astounding pace. At ESMO 2023, Syneos Health surveyed more than 75 health care providers (HCPs) about how these advancements are being viewed by patients on the frontlines of clinical care.

Here is what we learned:

  • Treatment Modality and Mechanism of Action (MOA) Excitement. HCPs surveyed indicated excitement about multi-targeted antibodies (e.g., bi-specifics), next generation small molecules and antibody-drug conjugates (ADC). Overall, HCPs exhibit a high excitement for all molecular targets assessed.
  • Lung Cancer Focus and Continued Advances in Precision Medicine. Multiple landmark trial results in lung cancer highlighted that more patients with non-small cell lung cancer (NSCLC) are likely to benefit from drugs targeting molecular alterations. The results could potentially drive major changes in first-line treatment for patients with ALK-positive, RET and EGFR mutations.
  • Paradigm Changing Results in Cervical Cancer Could Evolve the Standard of Care. Results from multiple cervical cancer trials could lead to a major change in standards of care established two decades ago. One treatment has improved progression-free survival (PFS) rates at two years in high-risk patients, and an induction chemotherapy alongside chemoradiotherapy led to significantly improved PFS at five years in low-risk patients.
  • Impacting Treatment Preferences. Many oncologists who attended ESMO believe that data from the conference will likely result in changes to treatment approach across cancer types. The biggest change is expected in breast, lung and gastrointestinal cancers.

To learn more about our analysis of HCPs at ESMO 2023, please download the attached report. If you are looking for the expertise and insight needed for this field of medicine, explore what the Syneos Health Consulting team has to offer.


Nadja Ulrich
Senior Engagement Manager, Consulting
Syneos Health

Ankit Kumawat
Engagement Manager, Consulting
Syneos Health

Katya Magonova
Managing Director, Consulting
Syneos Health

Interested in Syneos Health?